Breadcrumb Navigation

Melanom: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02D

Stadium/Indikation inkl. Kurzinfo

Melanom – 1st und 2nd line
Melanom mit 1-5 messbaren Hirnmetastasen

Anti-PD1 + antiCTLA4 + Lenvatinib vs AntiPD1 + Lenvatinib

Kurztitel

Merck MK3475
Substudy 02D
(UmbrellaTrial)
NCT04700072

Offizieller Titel

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02D

PI

Prof. Reinhard Dummer

Zuständige Ärztin

Corinne Eggenschwiler

Tel. +41 43 253 03 96

Behandelnder Fachbereich

Dermatologische Klinik